Gastroesophageal Reflux Disease Clinical Trial
Official title:
Reflux-Induced Oxidative Stress in Barrett's Esophagus: Response, Repair, and Epithelial-Mesenchymal-Transition
Verified date | September 2023 |
Source | Dallas VA Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to elucidate mechanisms whereby oxidative stress induced by acute reflux esophagitis: 1) activates p38 to regulate proteins that control the G1/S cell cycle checkpoint, and 2) activates HIFs (hypoxia inducible factors) to cause autocrine VEGF (vascular endothelial growth factor) signaling that triggers the EMT (epithelial-mesenchymal-transition) program in Barrett's esophagus.
Status | Completed |
Enrollment | 15 |
Est. completion date | November 2017 |
Est. primary completion date | November 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - U.S. Veteran - Barrett's Esophagus Exclusion Criteria: - Inability to provide informed consent - Pregnancy or breastfeeding - Esophageal varices - Warfarin use - Coagulopathy that precludes safe biopsy of the esophagus - Comorbidity that precludes safe participation in the study |
Country | Name | City | State |
---|---|---|---|
United States | Dallas VA Medical Center | Dallas | Texas |
Lead Sponsor | Collaborator |
---|---|
Dallas VA Medical Center | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in esophageal mucosal inflammation using histopathological assessment from baseline to 14 days | Inflammation of the esophageal mucosa will be measured at baseline, 7 days, and at 14 days. Esophageal mucosal inflammation will be measured using esophageal mucosal biopsy specimens, and histopatholgical grading. Mucosal infiltration with inflammatory cells (neutrophils, eosinophils, and lymphocytes) will be measured. | day 0, day 7, and day 14 | |
Secondary | change in p38 pathway from baseline to 14 days | p38 and components of the p38 pathway will be measured in the esophageal mucosa at baseline, 7 days, and at 14 days | day 0, day 7, and day 14 | |
Secondary | change in phosoho-p38 from baseline to 14 days | phospho-p38 will be measured in the esophageal mucosa at baseline, day 7, and at day 14 | day 0, day 7, and day 14 | |
Secondary | Show oxidative DNA damage associated with p38 activation | OxiSelect Oxidative DNA Damage ELISA assay of Barrett's mucosa at baseline, day 7, and day 14 | day 0, day 7, and day 14 | |
Secondary | change in VEGF from baseline to 14 days | VEGF will be measured in the esophageal mucosa at baseline, 7 days, and at day 14 | day 0, day 7, and day 14 | |
Secondary | change in APE-1 from baseline to 14 days | APE-1 will be measured in the esophageal mucosa at baseline, day 7, and at day 14 | day 0, day 7, and day 14 | |
Secondary | change in NPM1 from baseline to 14 days | NPM-1 will be measured in the esophageal mucosa at baseline, day 7, and at day 14 | day 0, day 7, and day 14 | |
Secondary | change in phospho-NPM1 from baseline to 14 days | phospho-NPM1 will be measured in the esophageal mucosa at baseline, day 7, and at day 14 | day 0, day 7, and day 14 | |
Secondary | change in miRNA expression from baseline to 14 days | miRNAs will be measured in the esophageal mucosa and in exosomes isolated from the blood at baseline, day 7, and day 14 | day 0, day 7, and day 14 | |
Secondary | change in HIF expression from baseline to 14 days | HIF expression will be measured in the esophageal mucosa at baseline, day 7, and day 14 | day 0, day 7, and day 14 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02135107 -
A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients
|
Phase 3 | |
Completed |
NCT01432392 -
Symptom Control and Impact on Daily Life in Patients With Gastroesophageal Reflux Disease
|
N/A | |
Recruiting |
NCT01249482 -
Symptom Assessment for GERD Patients Receiving H. Pylori Eradication
|
N/A | |
Completed |
NCT01200550 -
The Study to Describe Symptom Control and Impact on Daily Life in Gastroesophageal Reflux Disease (GERD) Patients
|
N/A | |
Completed |
NCT01578642 -
Feasibility Study for Evaluating the Effect of Electrical Stimulation on Lower Esophageal Sphincter Pressure and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease
|
Phase 2 | |
Completed |
NCT00998244 -
Study to Evaluate the Effect of a Very Low Carbohydrate Diet on Gastroesophageal Reflux Disease
|
N/A | |
Unknown status |
NCT01128608 -
The Effect of High PCO2 Solution on Esophageal Acid Sensation
|
N/A | |
Completed |
NCT00978016 -
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
|
Phase 2 | |
Completed |
NCT00768196 -
Prevalence of EED and Quality of Life Evaluated by Gastroesophageal Reflux Disease (GERD)-Q in Korean GERD Patients
|
N/A | |
Completed |
NCT00768443 -
Symptoms and Management Strategies in Gastroesophageal Reflux Disease (GERD)
|
N/A | |
Recruiting |
NCT00498082 -
Determinants of Efficacy of EsophyX Treatment in Gastro-Esophageal Reflux Disease
|
N/A | |
Completed |
NCT00886197 -
Diagnostic Efficacy of Narrow Band Imaging in Patients With Gastroesophageal Reflux Disease
|
N/A | |
Completed |
NCT00378898 -
Feasibility of Placing Bravo PH Capsule in Proximal Esophagus
|
N/A | |
Completed |
NCT00217347 -
Evaluation of Efficiency of Esophageal Capsule Endoscopy in the Screening of Patients With Gastroesophageal Reflux Disease or Dyspepsia as Compared to Upper Endoscopy
|
N/A | |
Completed |
NCT00507377 -
Foreshortened Esophagus and Its Surgical Therapy
|
||
Completed |
NCT00165022 -
Development of a Novel Disease-Specific Quality of Life Questionnaire for Gastroesophageal Reflux Disease (GERD) Patients in Chinese Population
|
N/A | |
Completed |
NCT00214552 -
Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma.
|
Phase 3 | |
Completed |
NCT00625495 -
Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
|
Phase 4 | |
Completed |
NCT00618150 -
Patient Education in Gastroesophageal Reflux Disease
|
N/A | |
Completed |
NCT03299985 -
Diaphragmatic Myofascial Release in Gastroesophageal Reflux Disease
|
N/A |